课题基金 / 基金详情

CORE--VIRAL PATHOGENESIS

CORE--VIRAL PATHOGENESIS
核心--病毒发病机制
批准号:
6500680
负责人:
Richard Syd Kornbluth
金额:
$18.05万
依托单位国家:
美国
项目类别:
财政年份:
2001
资助国家:
美国
项目状态:
已结题
起止时间:
2001-09-30 至 2002-05-31

项目摘要

项目成果

Richard Syd Kornbluth的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The Viral Pathogenesis Core serves as a centralized source for isolates and assays related to HIV-1, HIV-2, and SIV. In addition, the Core acts as an interface between users and the laboratories of UCSD CFAR members specializing in the herpes virus affecting HIV-infected individuals (CMV, HSV, and HHV-8). Four basic types of services are provided: (1) As a viral resource, the Core provides aliquots from a wide collection of characterized and titered viral strains of HIV-1, HIV-2, and SIV. (2) As a cell resource, the Core provides virus susceptible cells, including cell lines, isolated CD4+ T cells and macrophages. (3) As a virus characterization resource, the Core provides testing for cell tropisms, syncytium-inducing (SI) versus non-SI, co-receptor usage, cytopathic versus non-cytopathic, replication kinetics, drug susceptibilities, and other properties of HIV. (4) As a screening service, the Core provides the initial testing for investigational therapeutics (antiviral compounds, gene therapies, antibody neutralization, etc.). These resources make it easier for both novices and experienced investigators to pursue their virological research ideas. Without the Core, each investigator would need to set up and validate the different methods and assays required for their work, which could take months. Also, many of the Core's users have no BL3 training or experience themselves, and thus would need to expend months of effort on gaining the permission needed to work with these viruses. While the Core is not meant to replace a full scale research program set up by an investigator as one of the major projects, it is ideal for conducting pilot experiments and the screening of compounds for antiviral activity.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
MagaVax vaccine for Ebola
  • 批准号:
    9254569
  • 项目类别:
  • 资助金额:
    $22.5万
  • 财政年份:
    2016
  • 负责人:
    Richard Syd Kornbluth
  • 依托单位:
Ovarian cancer therapy using CD40 Ligand (CD40L)
  • 批准号:
    8648384
  • 项目类别:
  • 资助金额:
    $22.39万
  • 财政年份:
    2014
  • 负责人:
    Richard Syd Kornbluth
  • 依托单位:
Development of a multimeric CD40 ligand vaccine adjuvant
  • 批准号:
    8456940
  • 项目类别:
  • 资助金额:
    $30.0万
  • 财政年份:
    2013
  • 负责人:
    Richard Syd Kornbluth
  • 依托单位:
Development of a multimeric CD40 ligand vaccine adjuvant
  • 批准号:
    8715683
  • 项目类别:
  • 资助金额:
    $29.34万
  • 财政年份:
    2013
  • 负责人:
    Richard Syd Kornbluth
  • 依托单位:
海外基金